Press-release for stocks

Prices are updated after-hours

lungs

save search

BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
Published: 2024-04-23 (Crawled : 12:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K

Health Technology

| 5.97% | O: 3.5% H: 4.77% C: 2.39%
lung approval cancer cell treatment for

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
Published: 2024-04-22 (Crawled : 18:00) - biospace.com/
LTRN | News | $5.8 1.4% 1.38% 130K

Health Technology

| 8.05% | O: 6.74% H: 5.26% C: 0.35%
lung pharma japan approval cancer cell for trial

IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer
Published: 2024-04-22 (Crawled : 12:00) - biospace.com/
IDYA | News | $39.025 3.82% 3.68% 490K

Health Technology

| 2.9% | O: -0.82% H: 2.42% C: -0.05%
ide397 lung cancer cell expansion for

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung
Published: 2024-04-22 (Crawled : 11:00) - globenewswire.com
KRYS | News | $162.175 3.13% 3.04% 220K

Health Technology

| -0.66% | O: -2.94% H: 1.5% C: -0.68%
kb707 first lung biotech tumors treatment for trial advanced

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
IMMP | $2.53 9.05% 8.3% 72K

Health Technology

| 7.73% | O: -6.87% H: 0.0% C: 0.0%
tacti-004 lung positive cancer cell for trial

BostonGene and Saga University Announce Collaboration to Uncover Biomarkers for Improved Immunotherapy Response in Lung Cancer Patients
Published: 2024-04-16 (Crawled : 13:00) - biospace.com/
NIPNF | $66.9 -52.94% 140

Technology Services

| Email alert Add to watchlist
lung cancer immunotherapy for collaboration saga response biomarkers

Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024
Published: 2024-04-10 (Crawled : 20:00) - globenewswire.com
LUNG | $7.505 1.42% 1.4% 240K

Health Technology

| -9.86% | O: 0.12% H: 0.84% C: 0.24%
first report financial results

bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening
Published: 2024-04-09 (Crawled : 13:00) - biospace.com/
BIAF | $2.56 -14.67% -17.19% 400K

| -11.0% | O: -7.22% H: 0.0% C: -3.33%
lung initiative cancer for

CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting
Published: 2024-04-09 (Crawled : 13:00) - biospace.com/
CDNA | $8.21 0.49% 0.49% 450K

Health Technology

| -13.64% | O: 0.63% H: 5.84% C: 3.75%
lung international for meeting heart

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Published: 2024-04-09 (Crawled : 12:30) - prnewswire.com
GNPX | $2.32 7.26% 6.77% 30K

Health Technology

| -21.96% | O: 2.36% H: 6.6% C: 1.32%
reqorsa lung report positive treatment system preclinical for meeting therapy

American Lung Association and LUNGevity Foundation Announce $3 Million Research Partnership to Intercept Lung Cancer
Published: 2024-04-09 (Crawled : 11:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| -1.41% | O: -0.3% H: 0.0% C: 0.0%
partnership lung association million cancer research foundation

Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
Published: 2024-04-08 (Crawled : 12:30) - globenewswire.com
NVCT | $6.63 -6.62% -7.09% 39K

| -15.02% | O: 0.45% H: 0.51% C: 0.26%
nxp900 lung cancer cell

eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
Published: 2024-04-04 (Crawled : 12:30) - globenewswire.com
EFTR | $1.92 7.87% 7.29% 150K

| -87.36% | O: -76.55% H: 13.89% C: -17.78%
lung cancer cell topline trial therapeutics results

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-04 (Crawled : 12:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M

Health Technology

| -2.79% | O: 0.24% H: 0.08% C: -2.42%
mk-1084 keytruda lung merck cancer cell treatment trial

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Published: 2024-04-03 (Crawled : 12:30) - prnewswire.com
GNPX | $2.32 7.26% 6.77% 30K

Health Technology

| -18.66% | O: 1.76% H: 13.15% C: 7.61%
reqorsa lung cancer treat cell trial therapy study

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
Published: 2024-04-02 (Crawled : 20:00) - globenewswire.com
NBTX | $5.79 1.05% 1.04% 27K

Manufacturing

| -6.39% | O: 3.11% H: 1.19% C: -2.54%
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| -5.12% | O: 0.02% H: 0.0% C: 0.0%
lung cancer treatment

Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer
Published: 2024-04-02 (Crawled : 20:00) - globenewswire.com
RMD | $184.22 2.15% 0.0% 1.2M

Health Technology